SolarWinds to Showcase Application-Centric Performance Management Portfolio at VMworld 2017 Europe
SolarWinds Head Geek(TM) and VMware® vExpert, Thomas LaRock, will present best practices for monitoring and optimizing virtualized database servers in an interactive session
CORK, Ireland, Sept. 05, 2017 (GLOBE NEWSWIRE) -- SolarWinds, a leading provider of powerful and affordable IT management software, today announced its participation at VMworld® 2017 Europe, September 11-14, 2017, in Barcelona, Spain. At the event, SolarWinds Head Geek and VMware vExpert, Thomas LaRock, along with David Klee, will present on performance tuning and monitoring for virtualized database servers on Wednesday, September 13, 2017 from 12:30-1:30 p.m. CEST. The company will also demonstrate updates to the SolarWinds® Orion® Platform and across its systems management product portfolio.
"Databases are at the heart of most applications. Mission-critical database platforms require a different approach to virtualization from other applications," said LaRock. "Critical databases are resource-intensive, latency-sensitive, and are often the last to migrate to a virtualized environment. In my interactive session, I'll share tips on how to successfully virtualize database platforms, optimize performance, and address scalability concerns so that DBAs can avoid the blame game with the infrastructure team."
Join "Performance Tuning and Monitoring for Virtualized Database Server s"
On Wednesday, September 13, 2017 from 12:30-1:30 p.m. CEST, David Klee, founder and chief architect, Heraflux Technologies and LaRock will present the breakout session, "Performance Tuning and Monitoring for Virtualized Database Servers." During the session, Klee and LaRock will address how to validate your VMware environment and manage performance; how to scale database virtual machines upwards and outwards; and how to perfect database virtualization from a technical and organizational level.
LaRock is a Head Geek at SolarWinds and a VMware® vExpert, Microsoft® Certified Master, SQL Server® MVP, and a Microsoft Certified Trainer. He has over 15 years' experience in the IT industry in roles including programmer, developer, analyst, and database administrator.
Visit SolarWinds at Booth B524
- PerfStack(TM) dashboard improvements: Provides operations teams with a single dashboard to view real-time application metrics from application to spindle performance.
- Enhanced Internet of Things (IoT) device monitoring: Includes devices powered by Raspberry Pi, with new support for ARM-based Linux in the monitoring agent.
- Optimized virtual resource performance and virtualization management: Allows users to apply multiple predictive recommendations at once based on historic trends. Notably, Virtualization Manager (VMAN) no longer requires a separate appliance for polling; it's now all on the Orion Platform.
- Stronger support for Flash storage monitoring in Storage Resource Monitor (SRM): For IBM DS 8xxx, IBM FlashSystem A9000 and A9000R, NetApp EF, NetApp AFF, EMC VMAX3; also includes improvements in hardware health monitoring for storage devices.
- Improved Enterprise Operations Console (EOC): Includes a "monitor of monitors" to simplify global, multi-data center monitoring of systems and applications at scale.
- Simplified Orion Platform installer and new platform-native capabilities: The Orion Platform now includes disaster-recovery capabilities in addition to High Availability.
These enhancements will empower IT professionals with better application-centric performance management across their hybrid IT infrastructure.
About the SolarWinds Orion Platform
The Orion Platform is a modular and scalable, unified monitoring platform. It allows IT departments to add modules as their needs grow, providing ever richer visibility into their environments. While these modules are sold as individual products, they run on a unified platform, with a single web-based dashboard, centralized management and access control, unified alerting and reporting, and consolidated metrics and data - which enables context-rich dashboards that centralize data from multiple parts of the stack into an application-centric view. The SolarWinds Orion Platform is trusted by 425 of the Fortune 500® companies to monitor, visualize, and analyze the performance of networks, applications, systems, and databases on-premises, in a hybrid environment, or in the cloud.
For more information on SolarWinds IT management products, including downloadable, free 30-day evaluations, visit the SolarWinds website or call +353 21 500 2900.
Connect with SolarWinds
SolarWinds provides powerful and affordable IT management software to customers worldwide, from Fortune 500® enterprises to small businesses, managed service providers (MSPs), government agencies, and educational institutions. We are committed to focusing exclusively on IT, MSP, and DevOps professionals, and strive to eliminate the complexity that our customers have been forced to accept from traditional enterprise software vendors. Regardless of where the IT asset or user sits, SolarWinds delivers products that are easy to find, buy, use, maintain, and scale while providing the power to address key areas of the infrastructure from on-premises to the cloud. This focus and commitment to excellence in end-to-end hybrid IT performance management has established SolarWinds as the worldwide leader in both network management software and MSP solutions, and is driving similar growth across the full spectrum of IT management software. Our solutions are rooted in our deep connection to our user base, which interacts in our THWACK online community to solve problems, share technology and best practices, and directly participate in our product development process. Learn more today at www.solarwinds.com.
The SolarWinds, SolarWinds & Design, Orion, and THWACK trademarks are the exclusive property of SolarWinds Worldwide, LLC or its affiliates, are registered with the U.S. Patent and Trademark Office, and may be registered or pending registration in other countries. All other SolarWinds trademarks, service marks, and logos may be common law marks or are registered or pending registration. All other trademarks mentioned herein are used for identification purposes only and are trademarks of (and may be registered trademarks of) their respective companies.
© 2017 SolarWinds Worldwide, LLC. All rights reserved.
Phone: +44 (0)7974 161 187
Phone: +353 21 500 2954
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: SolarWinds Worldwide, LLC via Globenewswire
Följ NASDAQ OMX
Skriv in din e-postadress så får du ett mejl när vi har något nytt att berätta.
Senaste pressmeddelandena från NASDAQ OMX
XBiotech to Present at Cantor Fitzgerald's Global Healthcare Conference21.9.2017 14:00 | Pressmeddelande
AUSTIN, Texas, Sept. 21, 2017 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today that management will be presenting at Cantor Fitzgerald's Global Healthcare Conference taking place September 25-27 at the InterContinental New York Barclay Hotel in New York City. Mr. Benjamin Guzman, the Company's Senior Vice President of Corporate Strategy & Finance, will provide a corporate overview on Wednesday, September 27th at 2:50pm Eastern Time. About True Human(TM) Therapeutic Antibodies Unlike previous generations of antibody therapies, XBiotech's True Human(TM) antibodies are derived without modification from individuals who possess natural immunity to certain diseases. With discovery and clinical programs across multiple disease areas, XBiotech's True Human antibodies have the potential to harness the body's natural immunity to fight disease with increased safety, efficacy and tolerability. About XBiotech
At the 10th anniversary of the iPhone, Chairman of Pilatus Bank draws a stark comparison of the role technology has played in banking vs telecommunication21.9.2017 08:58 | Pressmeddelande
LONDON, Sept. 21, 2017 (GLOBE NEWSWIRE) -- Ali Sadr, Chairman of Pilatus Bank, believes that banks have failed to capture the true essence of technology for improving quality of service, as well as lacking the vision necessary to capture customers' imaginations. Meanwhile, other industries have been revolutionized and continue to thrive by the same technology. America has in the last 10 years been forced to close 10,000 branches. Since 2008, Europe has lost close to 48,000 branches, which is more than 20% of its branch network. There is little doubt that branch banking is on the decline, and online banking is failing to provide a quality service. As we mark the 10th anniversary of the iPhone, Ali Sadr, Chairman of Pilatus Bank, gives a sobering count of the current state of affairs in the use of technology among well established banks, and elaborates on a vision that has the potential to become the largest revolution the banking industry is yet to experience. Chairman Al
Immunicum AB (publ) presenterar prekliniska data om ilixadencels verkningsmekanism på SITC-mötet i USA21.9.2017 08:00 | Pressmeddelande
Pressmeddelande 21 september 2017 Immunicum AB (publ) presenterar prekliniska data om ilixadencels verkningsmekanism på SITC-mötet i USA Immunicum AB (publ; First North Premier: IMMU.ST), ett bioteknikbolag som utvecklar nya immunostimulerande cancerbehandlingar för ett antal solida tumörer, meddelar idag att Society for Immunotherapy of Cancer (SITC) har accepterat att ett abstract kring ilixadencels verkningsmekanism presenteras som poster vid SITCs 32:a årsmöte som hålls 8-12 november, 2017 i Gaylord National Hotel & Convention Center i National Harbor, Maryland. Postern med titeln "In vitro mode of action of ilixadencel - a cell-based allogeneic immune primer for intratumoral administration" presenteras av Immunicums forskningschef Alex Karlsson-Parra. Immunicum kommer att offentliggöra fullständiga data i ett pressmeddelande efter presentationen. När datum och tidpunkt för presentationen offentliggjorts kommer detta att fi
Immunicum AB (publ) to Present Preclinical Data on Ilixadencel's Mode of Action at the SITC Meeting in the US21.9.2017 08:00 | Pressmeddelande
Press Release 21 September 2017 Immunicum AB (publ) to Present Preclinical Data on Ilixadencel's Mode of Action at the SITC Meeting in the US Immunicum AB (publ; First North Premier: IMMU.ST) a biopharmaceutical company advancing a novel immune-priming cancer treatment against a variety of solid tumors, today announced that the Society for Immunotherapy of Cancer (SITC) has accepted an abstract on ilixadencel's mode of action for a poster presentation at the SITC 32 nd Annual Meeting, held November 8-12, 2017 at the Gaylord National Hotel & Convention Center in National Harbor, Maryland. The poster titled "In vitro mode of action of ilixadencel - a cell-based allogeneic immune primer for intratumoral administration" will be presented by Immunicum's Chief Scientific Officer, Alex Karlsson-Parra. Immunicum will announce the complete data through a press relea
Asure Software to Attend at Quora Consulting's Smartworking Summit21.9.2017 07:00 | Pressmeddelande
Asure Join's Industry Leaders to Discuss "Understanding the Productivity Enigma" AUSTIN, Texas, Sept. 21, 2017 (GLOBE NEWSWIRE) -- Asure Software, (NASDAQ:ASUR), a leading provider in human capital management and workspace management software, will be sponsoring Quora Consulting's Smartworking Summit in central London, September 28th 2017. These summits have continued to lead in addressing work space issues, such as occupancy, utilization, and productivity in the workforce. Dominic Jackson, Asure Sales Director of EMEA commented, "It is workplace issues like productivity that have driven thought leadership here at Asure." He continued "Utilization of workspace solutions help you recruit and retain the best talent, improve employee productivity, streamline operations, and realize a significant ROI on your most valuable assets - people, space and technology. We are thrilled to be not only part of the discussion, but part of the solu
Abiomed Receives FDA PMA Approval for Impella RP® for Right Heart Failure21.9.2017 00:23 | Pressmeddelande
DANVERS, Mass., Sept. 20, 2017 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support and recovery technologies, today announced it has received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) for the Impella RP® heart pump. Culminating from five years of research, this approval follows the prior FDA Humanitarian Device Exemption (HDE) received in January 2015 and adds the Impella RP heart pump to Abiomed's platform of PMA approved devices. With this approval, the Impella RP heart pump is the only percutaneous temporary ventricular support device that is FDA-approved as safe and effective for right heart failure as stated in the indication: The Impella RP System is indicated for providing temporary right ventricular support for up to 14 days in patients with a body surface area greater than or equal to 1.5 m2, who develop acute right heart failure or decompensation following left ventricular assist device impl
I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt pressrum